Healthcare Unfiltered

Latest Episodes:

Episode 8: Real-World Evidence and Value-Based Care in the Academic World Dec 01, 2020

Show notes

Yousuf Zafar (@yzafar), MD, GI oncologist and associate professor of medicine, Duke University, highlights perspectives that are missing from the “general rubric” of value-based care in oncology, how real-world evidence (RWE) can help augment takeaways from clinical trial data, issues of capturing the patient voice in real-world data and electronic health records, and how the FDA is utilizing RWE for expanding drug indications. Dr. Zafar shares where he sees the intersection between RWE and value-based care existing from a payer perspective as well why he believes the COVID-19 pandemic provides “fertile ground” for the prevalence of RWE.

Episode 7: Direct-To-Consumer Advertising in Healthcare: Legality and Ethics Nov 24, 2020

Show notes

Alison Bateman-House (@ABatemanHouse), MPH, PhD, medical ethicist at New York University’s School of Medicine, explains the distinction between direct-to-consumer (DTC) advertising of doctors and drugs to that of consumer goods, as well as regulatory and ethical concerns of DTC advertising on the part of hospitals and drugs. Chadi and Dr. Bateman-House grapple with questions of whether healthcare is simply a consumer good or if it is something more and whether DTC advertising should be banned in healthcare altogether.

Episode 6: Advocacy in a Time of Uncertainty: Jill Feldman’s Ongoing Battle With Lung Cancer Nov 17, 2020

Show notes

Jill Feldman (@jillfeldman4), lung cancer survivor and advocate, shares her familial history of lung cancer that drove her to advocacy work long before her own diagnosis of EGFR-positive disease, as well as her treatment courses with erlotinib and subsequent SBRT for many years before osimertinib. Jill then describes her “journey” in advocacy, beginning with self-advocacy and the LUNGevity Foundation, independent research advocacy and representing lung cancer patients, and co-founding the EGFR Resisters (@EGFRResisters) – a group of EGFR-positive patients who are resistant to targeted treatment. Her message for clinicians and scientists is to start thinking of patients as partners in research.

Episode 5: Measurable Residual Disease: Hype or Hope? Nov 10, 2020

Show notes

Ameet Kini (@AmeetRKini), MD, PhD, hematopathologist, and Patrick Hagan, MD, hematologist/oncologist, both at Loyola University Medical Center, deliberate on the clinical importance of MRD and how clinicians should utilize it, optimal techniques for detecting MRD in various diseases, the gap between academia and the community when it comes to MRD knowledge, the potential of MRD as a surrogate marker, and how to reconcile discordant MRD results from different vendors.

Episode 4: COIs in Medicine: A Broken System Oct 27, 2020

Show notes

Vincent Rajkumar (@VincentRK), MD, hematologist at the Mayo Clinic (Rochester, MN), shares the distinction between conflicts of interest that guide individual physicians and those that guide entire practices, what types of conflicts should be collected as “material” and which should be disregarded (eg, “transfer of value” payments), issues with disclosure expectations in modern medical research, and an idea to create standards for more appropriate and warranted disclosures.Watch a previous discussion Chadi had with Dr. Rajkumar on conflicts of interest https://www.medscape.com/viewarticle/924320

Episode 3: Expert Roundtable: Genitourinary Updates and Top Data Oct 20, 2020

Show notes

Chadi facilitates a discussion between three GU oncologists on the latest research and treatment updates in the field. Rana McKay (@DrRanaMcKay), MD, UC San Diego, Petros Grivas (@PGrivasMDPhD), MD, PhD, Fred Hutchinson Cancer Research Center, and Toni Choueiri (@DrChoueiri), MD, Dana-Farber Cancer Institute, debate the practice-changing potential of chosen papers and abstracts presented at ASCO and ESMO, including updated data on the final OS in the PROFOUND trial, context and implications of the JAVELIN trial for bladder cancer, ramifications of the CheckMate 9ER trial for kidney cancer, and more.

Episode 2: CRISPR: Monumental Technology and Noble Prize Winner Oct 13, 2020

Show notes

John Doench (@JohnDoench), PhD, Associate Director of the Genetic Perturbation Platform, Broad Institute of MIT and Harvard, joins Chadi for a fascinating discussion on the history of CRISPR as a scientific breakthrough, the ease of merging CRISPR technology into human cells, challenges remaining for CRISPR to become a widely used clinical tool and ultimately helping patients, and much more.

Episode 1: Cardiology, COVID-19, and College Sports: What Went Wrong Oct 06, 2020

Show notes

In the inaugural episode of Healthcare Unfiltered, host Chadi Nabhan invites cardiologists Venk Murthy (@venkmurthy), MD, University of Michigan, and Anish Koka (@anish_koka), MD, private practice in Philadelphia, to contextualize the effects of COVID-19 on the heart, as explained in a flawed JAMA Cardiology publication that was close to having such trickle down effects as cancelling college sports across the US. The trio explains how the study should not be used to treat patients with preexisting cardiac conditions and COVID-19, the dangers of using the study as grounds for social policy, the importance of post-publication peer-review (via social media), and much more.View the JAMA Cardiology publication https://jamanetwork.com/journals/jamacardiology/fullarticle/2768916

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected